Ametek Stock Hits New 52-Week High (AME)

NEW YORK ( TheStreet) -- Ametek (NYSE: AME) hit a new 52-week high Thursday as it is currently trading at $49.94, above its previous 52-week high of $49.71 with 75,797 shares traded as of 9:55 a.m. ET. Average volume has been 617,200 shares over the past 30 days.

Ametek has a market cap of $7.8 billion and is part of the industrial goods sector and industrial industry. Shares are up 16.9% year to date as of the close of trading on Wednesday.

AMETEK, Inc. manufactures and sells electronic instruments and electromechanical devices in North America, Europe, Asia, and South America. The company operates in two segments, Electronic Instruments Group and Electromechanical Group. The company has a P/E ratio of 20.5, equal to the average industrial industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Ametek as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Ametek Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Apple Gains as U.S. China Trade Tensions Ease After Weekend Summit

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI